



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/762,714

01/22/2004

Maxwell Gordon

1360-001

5204

47888 7590 09/30/2008  
HEDMAN & COSTIGAN P.C.  
1185 AVENUE OF THE AMERICAS  
NEW YORK, NY 10036

EXAMINER

CLAYTOR, DEIRDRE RENEE

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

09/30/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

|                              |                                      |  |  |
|------------------------------|--------------------------------------|--|--|
| <b>Office Action Summary</b> | <b>Application No.</b><br>10/762,714 | <b>Applicant(s)</b><br>GORDON, MAXWELL |  |
|                              | <b>Examiner</b><br>Renee Claytor     | <b>Art Unit</b><br>1617                |  |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 04 August 2008.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-6, 16-18, 21 and 22 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-6, 16-18, 21-22 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

### ***Request for Continued Examination***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/4/2008 has been entered.

### ***Response to Arguments***

Applicants have amended claim 22 to overcome the 35 USC 112 rejection by amending the claims to recite a method of treatment instead of a method for prevention. Accordingly, the rejection is withdrawn.

Applicants argue over the 35 USC 103 rejection that Oshlack does not mention a composition having the components of claim 1. Further, Applicants argue that the present claims recite a formulation where the pellets are enteric coated pellets and point out a specific three pellet formulation wherein the pellets are formulated to release the drugs in a specific anatomical location of the small intestine. Applicants submit that Oshlack does not teach these compositions.

In response to the above arguments, it is noted that the Oshlack reference does render obvious the present invention because Oshlack renders obvious the hydrocolloids and excipients listed in claim 1 as discussed in the rejection. Oshlack

Art Unit: 1617

teaches that the excipients as claimed can be used in the composition. Further, the excipients listed are commonly used in pharmaceutical compositions. Accordingly, the rejection is deemed proper and a new rejection is given below.

### ***Claim Rejections – 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-6, 16-17 and 21 rejected under 35 U.S.C. 103(a) as being unpatentable over Oshlack et al. (US Patent 7,144,587) in view of Meissner et al (Pain 84, 2000, 105-109).

Oshlack et al. teach solid dosage forms of compositions comprised of an opiate, an opiate antagonist and a hydrocolloid containing excipient (meeting the limitation of claim 1; Col. 6, lines 16-20). More specifically the opiates are chosen from agents such as morphine, codeine and oxycodone (meeting the limitation of claims 2-3; see Col. 12, lines 34-56 for a more complete list). Antagonists that are useful in the invention include naltrexone and naloxone (meeting the limitation of claims 4-5; lines 14-15). Dosage forms are taught that include coated beads including the composition (meeting the limitation of claim 6; Col. 17, lines 23-61). In regards to the limitation that the amount of the enteric coated opiate antagonist pellets is effective to prevent opiate induced constipation, it would be obvious that because Oshlack et al. teach coated

Art Unit: 1617

beads, it would necessarily prevent opiate induced constipation. It is taught that gelling agents or other excipients are included in the dosage forms, which include starch and starch derivatives, lactose, xanthan gum, locust bean gum, microcrystalline cellulose, alginates, dicalcium phosphate (dibasic calcium phosphate) and magnesium stearate (Col. 7, lines 20-47; Col. 16, lines 48-55 and Example 6). It is noted that the teaching of dicalcium phosphate renders the monocalcium phosphate obvious because the compounds are similar and have similar properties of being excipients. Selection of a known material based on its suitability for its intended use is obvious absent a clear showing of unexpected results attributable to the Applicant's specific selection. See e.g., *In re Leshin*, 227 F.2d 197, 125 USPQ 416 (CCPA 1960). The gelling agents impart a gel-like quality to the dosage form if it is tampered with and prevent abuse of the dosage form by minimizing absorption (Col. 7, lines 48-55). It is further taught that when the dosage form is tampered with and exposed to a small amount of a liquid such as water, the dosage form will be unsuitable for injection (meeting the limitation of claim 18; Col. 3, lines 12-16). Table 1 exemplifies a composition comprised of oxycodone with naloxone. Further, Oshlack et al. teaches that the opiate/opioid antagonist formulation together with a hydrocolloid can be formulated in immediate release formulations or controlled release in any suitable tablet (Col. 17, lines 12-15), and teaches coated beads that can contain the opiate, the opiate antagonist and hydrocolloid. Therefore, it would be obvious that one tablet could contain beads that are controlled and immediate release (meeting the limitation of claim 16-17). Further, because Oshlack et al. teach compositions comprised of the same components, it

Art Unit: 1617

would be obvious that the composition would be released in the same areas, such as the colon (further addressing claim 16).

Oshlack et al. does not specifically teach a compound comprised of all the ingredients listed in claim 1 nor does it teach that the composition is used in a method of treating constipation.

Meissner et al. teaches improved laxation during oral naloxone treatment in opioid-associated constipation (see whole document).

Accordingly, it would be obvious to a person having ordinary skill in the art at the time of the invention to formulate a composition comprised of an opiate, an opiate antagonist, hydrocolloids and other excipients as exemplified in claim 1 because Oshlack et al. teach the suitability of all of the hydrocolloids and excipients in a composition of coated beads with an opiate and an opiate antagonist. One would be motivated to include the hydrocolloids and excipients in the composition in an effort to form a composition that when tampered with will impart a gel-like quality to avoid abuse of the opiate composition (as taught by Oshlack et al., Col. 7, lines 48-55). One would be further motivated to use the composition in a method of treating constipation associated with the use of opioids because of Meissner's teachings that the combination of an opioid agonist and antagonist effectively treats constipation induced by the opiate.

### ***Conclusion***

No claims allowed.

***Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1617